133 related articles for article (PubMed ID: 35833288)
1. Indeterminate skeletal and lymph node lesion on 18F PSMA 1007 PET/CT scanning: lessons from a review at 12 months with PSMA-RADS.
Bhoil A; Seshadri N; Vinjamuri S
Nucl Med Commun; 2022 Sep; 43(9):1034-1041. PubMed ID: 35833288
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
4. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
5. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
6. Association of True Positivity with Serum Prostate-Specific Antigen Levels and Other Clinical Factors in Indeterminate PSMA-RADS-3A Lesions Identified on
Garg T; Werner RA; Chung HW; Khatri W; Pienta KJ; Pomper MG; Gorin MA; Saad E; Rowe SP
Tomography; 2022 Oct; 8(6):2639-2647. PubMed ID: 36412679
[TBL] [Abstract][Full Text] [Related]
7.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
8.
Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
[TBL] [Abstract][Full Text] [Related]
9. Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
Yin Y; Werner RA; Higuchi T; Lapa C; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
J Nucl Med; 2019 Apr; 60(4):511-516. PubMed ID: 30190303
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of early imaging with
Özülker F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):100-105. PubMed ID: 30514659
[TBL] [Abstract][Full Text] [Related]
11. Bone metastases in prostate cancer - Gallium-68-labeled prostate-specific membrane antigen or Fluorine 18 sodium fluoride PET/computed tomography - the better tracer?
Agrawal A; Natarajan A; Mithun S; Bakshi G; Joshi A; Murthy V; Menon S; Purandare N; Shah S; Puranik A; Choudhury S; Prakash G; Pal M; Maitre P; Prabhash K; Noronha V; Rangarajan V
Nucl Med Commun; 2022 Dec; 43(12):1225-1232. PubMed ID: 36345767
[TBL] [Abstract][Full Text] [Related]
12.
Esen T; Falay O; Tarim K; Armutlu A; Koseoglu E; Kilic M; Seymen H; Sarikaya AF; Kiremit MC; Balbay MD; Canda AE; Baydar DE; Kordan Y; Demirkol MO; Tilki D
Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
[TBL] [Abstract][Full Text] [Related]
13. Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients.
Grawe F; Blom F; Winkelmann M; Burgard C; Schmid-Tannwald C; Unterrainer LM; Sheikh GT; Pfitzinger PL; Kazmierczak P; Cyran CC; Ricke J; Stief CG; Bartenstein P; Ruebenthaler J; Fabritius MP; Geyer T
Eur Radiol; 2024 Feb; 34(2):1157-1166. PubMed ID: 37624414
[TBL] [Abstract][Full Text] [Related]
14. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on
Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP
J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304
[TBL] [Abstract][Full Text] [Related]
15. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
16. Impact of piflufolastat F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states: A retrospective review.
Arafa AT; Jain A; Skrobanek P; Humphrey B; Froelich JW; Antonarakis ES
Prostate; 2023 Jun; 83(9):863-870. PubMed ID: 36999911
[TBL] [Abstract][Full Text] [Related]
17. [
Hirmas N; Al-Ibraheem A; Herrmann K; Alsharif A; Muhsin H; Khader J; Al-Daghmin A; Salah S
Mol Imaging Biol; 2019 Jun; 21(3):574-581. PubMed ID: 30215174
[TBL] [Abstract][Full Text] [Related]
18. Predicting Outcomes of Indeterminate Bone Lesions on
Phelps TE; Harmon SA; Mena E; Lindenberg L; Shih JH; Citrin DE; Pinto PA; Wood BJ; Dahut WL; Gulley JL; Madan RA; Choyke PL; Turkbey B
J Nucl Med; 2023 Mar; 64(3):395-401. PubMed ID: 36265908
[TBL] [Abstract][Full Text] [Related]
19. The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0.
Kuten J; Dekalo S; Mintz I; Yossepowitch O; Mano R; Even-Sapir E
EJNMMI Res; 2021 Jan; 11(1):3. PubMed ID: 33409930
[TBL] [Abstract][Full Text] [Related]
20. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
